Study Title
REACH2: A Phase III Randomized Open-Label Multi-centre Study of Ruxolitinib versus best available therapy in patients with Corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation
Protocol ID
REACH2
Condition/s
Corticosteroid Refractory Acute Graft vs Host Disease
Diagnosis Stage
Previously treated
Sponsor
Novartis Pharmaceuticals
Links
Trial Status
Completed
Trial Close Date
23/04/2021
Study Type
Parallel Assignment
Phase
Phase 3
Age Eligibility
12 Years and older
International registry ID's
NCT02913261
| Study Title | REACH2: A Phase III Randomized Open-Label Multi-centre Study of Ruxolitinib versus best available therapy in patients with Corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation |
|---|---|
| Protocol ID | REACH2 |
| Disease (Sub Disease) | Corticosteroid Refractory Acute Graft vs Host Disease |
| Diagnosis Stage | Previously treated |
| Sponsor | Novartis Pharmaceuticals |
| Links | https://clinicaltrials.gov/ct2/show/NCT02913261 |
| Trial Status | Completed |
| Trial Open Date | 10/03/2017 |
| Trial Close Date | 23/04/2021 |
| Study Type | Parallel Assignment |
| Phase | Phase 3 |
| Age Eligibility | 12 Years and older |
| International registry ID's | NCT02913261 |